Abstract: Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding to CXCR2 and CXCR4 and/or (ii) MIF-activation of CXCR2 and CXCR4; (iii) the ability of MIF to form a homomultimer; or a combination thereof.
Type:
Application
Filed:
March 20, 2009
Publication date:
October 27, 2011
Applicant:
CAROLUS THERPEUTICS, INC.
Inventors:
Jürgen Bernhagen, Joshua Robert Schultz, Benedikt Vollrath, Alma Zernecke, Christian Weber
Abstract: Described herein are methods for treating or preventing a atherosclerosis by inhibiting the activation or binding of macrophage migration inhibitory factor to CXCR2 and CXCR4. Such inhibition is achieved by administration of either a single agent or a combination of agents. Also described herein are agents that inhibit MIF-binding or MIF-activation of CXCR2 or CXCR4. Further described are pharmaceutical compositions comprising such agents and their use for treating or preventing atherosclerosis.
Type:
Application
Filed:
March 24, 2008
Publication date:
March 24, 2011
Applicant:
CAROLUS THERPEUTICS, INC.
Inventors:
Jürgen Bernhagen, Christian Weber, Alma Zernecke
Abstract: Disclosed herein, in certain embodiments, is a method for treating an inflammatory disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding to CXCR2 and CXCR4 and/or (ii) MIF-activation of CXCR2 and CXCR4; (iii) the ability of MIF to form a homomultimer; or a combination thereof.
Type:
Application
Filed:
March 20, 2009
Publication date:
February 24, 2011
Applicant:
CAROLUS THERPEUTICS, INC.
Inventors:
Jürgen Bernhagen, Joshua Robert Schultz, Benedikt Vollrath, Alma Zernecke, Christian Weber